menu
    • menu
    [{"orgOrder":0,"company":"Center for Clinical Pharmacology Research Bdbeq S.A.","sponsor":"Laboratorio Elea Phoenix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Darifenacin Hydrobromide","moa":"Muscarinic acetylcholine receptor M2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Center for Clinical Pharmacology Research Bdbeq S.A.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Center for Clinical Pharmacology Research Bdbeq S.A. \/ Laboratorio Elea Phoenix","highestDevelopmentStatusID":"6","companyTruncated":"Center for Clinical Pharmacology Research Bdbeq S.A. \/ Laboratorio Elea Phoenix"},{"orgOrder":0,"company":"Center for Clinical Pharmacology Research Bdbeq S.A.","sponsor":"Laboratorio Elea Phoenix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Darifenacin Hydrobromide","moa":"Muscarinic acetylcholine receptor M2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Center for Clinical Pharmacology Research Bdbeq S.A.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Center for Clinical Pharmacology Research Bdbeq S.A. \/ Laboratorio Elea Phoenix","highestDevelopmentStatusID":"6","companyTruncated":"Center for Clinical Pharmacology Research Bdbeq S.A. \/ Laboratorio Elea Phoenix"}]

    Find Clinical Drug Pipeline Developments & Deals for Darifenacin Hydrobromide

    Menu

    Darifenacin Hydrobromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Center for Clinical Pharmacology Research Bdbeq S.A.

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Center for Clinical Pharmacology Research Bdbeq S.A.

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darifenacin Hydrobromide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Laboratorio Elea Phoenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.

                            Details : Darifenacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2010

                            Lead Product(s) : Darifenacin Hydrobromide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Laboratorio Elea Phoenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Center for Clinical Pharmacology Research Bdbeq S.A.

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Center for Clinical Pharmacology Research Bdbeq S.A.

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darifenacin Hydrobromide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Laboratorio Elea Phoenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.

                            Details : Darifenacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 25, 2010

                            Lead Product(s) : Darifenacin Hydrobromide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Laboratorio Elea Phoenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth